EQ101
Alzheimer's Disease
Key Facts
About Quince Therapeutics
Quince Therapeutics is dedicated to addressing the significant unmet medical need in neurodegenerative disorders through its precision medicine approach. The company's strategy centers on its lead program, EQ101, which is advancing through clinical development for Alzheimer's disease, with potential applications in other NLRP3-mediated conditions. Quince leverages its expertise in neuroinflammation biology to build a pipeline of targeted therapeutics, positioning itself in a competitive but high-value market segment. The company operates as a lean, focused organization with key leadership experienced in neuroscience drug development.
View full company profileAbout Quince Therapeutics
Quince Therapeutics is dedicated to addressing the significant unmet medical need in neurodegenerative disorders through its precision medicine approach. The company's strategy centers on its lead program, EQ101, which is advancing through clinical development for Alzheimer's disease, with potential applications in other NLRP3-mediated conditions. Quince leverages its expertise in neuroinflammation biology to build a pipeline of targeted therapeutics, positioning itself in a competitive but high-value market segment. The company operates as a lean, focused organization with key leadership experienced in neuroscience drug development.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Donanemab | Eli Lilly | Phase 3 |
| ALN-APP | Alnylam Pharmaceuticals | Phase 1 |
| Alzheimer's Disease Program | Roche | Various |
| UCB0022 | UCB | Phase 1 |
| Lecanemab (Leqembi) | Eisai | Commercial |
| ARO-MAPT | Arrowhead Pharmaceuticals | Pre-clinical |
| AMBAR® | Grifols | Clinical |
| Lu AG08854 (L1CAM mAb) | Lundbeck | Preclinical |
| DNL919 | Denali Therapeutics | Phase 1b |
| BAN2802 | BioArctic AB | Preclinical |
| Lecanemab SC | BioArctic AB | Phase 3 |
| Undisclosed Program | uniQure | Preclinical |